Actelion Ltd. Overview
Pro stress-test →Actelion Pharmaceuticals Ltd. is a pharmaceuticals and biotechnology company established in December 1997, headquartered in Allschwil near Basel, Switzerland, and is part of Johnson & Johnson Innovative Medicine business segment. Actelion focuses on the manufacture of drugs that treat rare and orphan diseases.
Strategic Profile
Pro stress-test →Actelion, a part of the Johnson & Johnson Family of Companies, is a global leader in the treatment of pulmonary arterial hypertension (PAH), a serious condition affecting the pulmonary arteries and the right side of the heart. The company has several products on the market, largely focused on pulmonary arterial hypertension: Tracleer, Opsumit, Uptravi, Ventavis, and Veletri treat various stages of the disease via different methods.
Competitive Landscape
Pro stress-test →Regeneron Pharmaceuticals, United Therapeutics, Grifols, AB Science, and ACADIA Pharmaceuticals are some of the competitors of Actelion Pharmaceuticals. Actelion competes primarily in the PAH therapeutic space against specialized and larger pharmaceutical companies offering alternative treatment modalities and patient pathways.
Industry Context
Actelion Ltd. operates in Rare disease pharmaceuticals.
Key facts
Founded: 1997 · Headquarters: Allschwil, Switzerland · Employees: 2,624